Latest LLYC news and sentiment

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned -7.3%, compared to the Zacks S&P 500 composite's -2.4% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has lost 0.6%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usu

Eli Lilly and QurCan sign genetic medicine deal

Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything

Berenberg Lifts Lilly to Buy With a $1,400 Target

This article first appeared on GuruFocus. Eli Lilly and Co. (NYSE:LLY) rose 1.27% premarket after Berenberg upgraded it to Buy from Hold and lifted its price target to $1,400 from $1,220, implying roughly 22% upside from current levels. The firm's 2026 return on research investment work found Lilly delivering best-in-class returns, and it expects the company to hold its lead in obesity. Warning! GuruFocus has detected 4 Warning Sign with DASH. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart Berenberg puts Lilly at roughly $60 billion year to date across m

There Are Plenty of Eli Lilly Bulls: Here’s What They Aren’t Telling You

Quick Read LLY beat Q2 earnings by 27% and raised full-year revenue guidance to $87B, yet the stock is a Hold as net prices fell 13% and management warned prices will keep dropping. LLY trades at 37 times trailing earnings but has lagged the S&P 500 this year, gaining just 6% versus SPY's 12%. Even after beating Q2 estimates by 13%, LLY dropped 14% on earnings day, signaling the market demands flawless execution at current prices. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see

Eli Lilly and Novo Nordisk have paid more than 270,000 doctors — one as much as $1M — to promote GLP-1 weight-loss drugs

Ilana Panich-Linsman/For The Washington Post via Getty Images It's hard to miss celebrity endorsements for weight-loss drugs from people like Serena Williams, who promoted GLP-1s this summer when she returned to the pro tennis circuit. She's signed a deal with Ro, a telehealth platform that sells GLP-1s directly to consumers. Not everyone is happy about Williams' turn as a weight-loss drug promoter. As Forbes reported, she got pushback for a similar spot during the Super Bowl. Must Read Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety profile and suggested the potential to provide cardiovascular benefits Lilly will unveil Phase 2 data for eloraTZP, our latest triple-acting medicine combining the selective amylin receptor agonist eloralintide and GIP/GLP-1 receptor agonist tirzepatide INDIANAPOLIS, Sept. 15, 2026 /PRNewswire/ -- Eli

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

Multi-program collaboration leveraging QurCan's TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO, September 15, 2026--(BUSINESS WIRE)--QurCan Therapeutics ("QurCan"), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company ("Lilly") for the treatment of diseases of the central nervous system (CNS) and peripheral ner

Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY)

Eli Lilly and Company recently presented at Morgan Stanley's Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This focus on widening obesity treatment access through consumer advertising, Medicare Bridge support, and global reach underlines how central these therapies have become to Lilly's long-term business mix. We'll now examine how Lilly's push to broaden access to obesity treatments, particularly via the Medicare Brid

Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve

Quick Read Eli Lilly (LLY) dropped 8% last month despite 48% revenue growth, leaving Citi's $1,600 Street-high target implying 45% upside. Novo Nordisk (NVO) offers only ~10% analyst upside and Merck (MRK) just ~6%, making Lilly the clear outlier for implied returns across pharma peers. Retatrutide showed bariatric-surgery-level weight loss in trials, with a BLA filing planned for Q1 2027 and oral GLP-1 Foundeo jumping from 8,000 to 36,000 prescribers in one quarter. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't

Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer

During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I've got a couple more running backs. Eli Lilly's become a great compounder thanks to its booming GLP-1 weight loss business. For an NFL comparison, we're going to have to stay in Indianapolis where Lilly's based, and give you Colts running back Jonathan Taylor, entering his seventh seaso

Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Eli Lilly and Company's LLY portfolio is overwhelmingly driven by its popular GLP-1 medicines, Mounjaro and Zepbound. However, the company's broader strategy is becoming increasingly clear — leverage the substantial cash flow generated by its cardiometabolic franchise to fund strategic acquisitions, expand its pipeline, and invest in research and development aimed at creating the next generation of growth drivers. Immunology is emerging as one of the most promising areas of this diversification strategy. Lilly's Immunology Portfolio Delivers Steady Revenue Growth Lilly's Immunology portfolio g

Eli Lilly Completes Acquisition of AtaiBeckley

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression. "Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. "Atai

Eli Lilly and Company: Konsensus der Analysten und Kursziel | 858560 | US5324571083

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Viking Therapeutics (NASDAQ: VKTX) has been one of the hopefuls in a big race. The biotech company aims to launch one of the world's next big weight loss drugs. The market, on track to reach nearly $100 billion by the end of the decade, today is dominated by pharma giants Eli Lilly and Novo Nordisk, but high demand for these products means there is room for other players to succeed here too. Viking is investigating its candidate in a phase 3 trial in injectable format and is preparing to launch a phase 3 trial for its oral formulation. Earlier trial results have been positive, making Viking a

The Zacks Analyst Blog Highlights Eli Lilly, Palo Alto, Texas Instruments and Stratus Properties

For Immediate Release Chicago, IL – September 10, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, Palo Alto Networks, Inc. PANW, Texas Instruments Inc. TXN and Stratus Properties Inc. STRS. Here are highlights from Wednesday's Analyst Blog: Top Analyst Reports for Eli Lilly, Palo Alto Networks and Texas Instruments The Zacks Research Daily presents the best research output of

Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I'll tell you… I think it's always good to look at Lilly as a stock that I think has a lot of things that are going well, but I want to wait. Well, actually, you know, tell you the truth… It's pulled back. I think you're fine, I think you're fine to add some. I'm going to okay that. And I understand JNJ's moved a great deal. It's been a great club hit

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

In the latest close session, Eli Lilly (LLY) was down 2.21% at $1,123.91. This change lagged the S&P 500's 0.58% loss on the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%. Shares of the drugmaker have depreciated by 6.7% over the course of the past month, underperforming the Medical sector's gain of 2.73%, and the S&P 500's loss of 0.36%. Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2026. It is anticipated that the c

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Eli Lilly and Company LLY boasts a wide range of products across cardiometabolic health, neuroscience, oncology and immunology. Cardiometabolic Health is Lilly's largest therapeutic area by a wide margin, particularly with the success of its tirzepatide medicines, Mounjaro and Zepbound. Its cardiometabolic products accounted for approximately 80% of Lilly's total revenues in the first half of 2026. However, Lilly is gradually building a more diversified portfolio by expanding in oncology, immunology and neuroscience. Lilly has also embarked on an aggressive M&A spree in the past couple of year

Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases

Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development SOUTH SAN FRANCISCO & SAN DIEGO, September 08, 2026--(BUSINESS WIRE)--Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interferen